Cellectis (CLLS) Change in Account Payables (2015 - 2026)
Cellectis' (CLLS) quarterly Change in Account Payables came in at -$3.9 million in Q1 2026, up 38.65% year-on-year from -$2.8 million in Q1 2025, and down 856.47% quarter-over-quarter from $510000.0 in Q3 2025.
Cellectis (CLLS) Change in Account Payables (2015 - 2026) Analysis & Trends
Cellectis' Change in Account Payables history runs 12 years deep, the most recent figure standing at -$3.9 million for Q1 2026.
- On a quarterly basis, Change in Account Payables rose 38.65% year-over-year to -$3.9 million in Q1 2026; TTM through Mar 2026 was -$9.6 million, a 682.31% decrease from a year earlier, with the FY2024 full-year figure at $2.1 million, up 132.59% from the prior year.
- Change in Account Payables eased to -$3.9 million in Q1 2026 per CLLS's latest filing, from $510000.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $7.3 million in Q2 2022 and bottomed at -$6.5 million in Q1 2022.
- The 5-year median for Change in Account Payables is -$106000.0 (2024), against an average of -$663562.5.
- Across the five-year window, Change in Account Payables sank 200.34% in 2023 and soared 524.47% in 2024, its largest moves.
- Year by year, Change in Account Payables stood at $1.8 million in 2022, then sank by 200.34% to -$1.8 million in 2023, then surged by 268.13% to $3.0 million in 2024, then slumped by 82.74% to $510000.0 in 2025, then slumped by 856.47% to -$3.9 million in 2026.
- Per Business Quant, the three latest CLLS Change in Account Payables figures stand at -$3.9 million (Q1 2026), $510000.0 (Q3 2025), and $23000.0 (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -42.19 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.52 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 16.86 Mn |
| 10 | Cellectis | 281.48 Mn | 95.81 Mn | - | -3.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.86 Mn |
| Mar 31, 2026 | -3.86 Mn |
| Sep 30, 2025 | 510,000.00 |
| Sep 30, 2025 | 510,000.00 |
| Jun 30, 2025 | 23,000.00 |
| Jun 30, 2025 | 23,000.00 |
| Mar 31, 2025 | -6.29 Mn |
| Mar 31, 2025 | -6.29 Mn |
| Dec 31, 2024 | 2.95 Mn |
| Dec 31, 2024 | 2.95 Mn |
| Sep 30, 2024 | -235,000.00 |
| Sep 30, 2024 | -235,000.00 |
| Jun 30, 2024 | 5.22 Mn |
| Jun 30, 2024 | 5.22 Mn |
| Mar 31, 2024 | -5.89 Mn |
| Mar 31, 2024 | -5.89 Mn |
| Dec 31, 2023 | -1.76 Mn |
| Dec 31, 2023 | -1.76 Mn |
| Sep 30, 2023 | 2.89 Mn |
| Sep 30, 2023 | 2.89 Mn |